W1P

5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one

Created:	2020-09-24
Last modified:	2021-01-13

Find Related PDB Entry
6 entries where W1P is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	23
Chiral Atom Count	0
Bond Count	24
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
Systematic Name (OpenEye OEToolkits)	5-methyl-2-phenyl-4~{H}-pyrazol-3-one
Formula	C₁₀ H₁₀ N₂ O
Molecular Weight	174.199
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	N2(c1ccccc1)C(=O)CC(=N2)C
SMILES	CACTVS	3.385	CC1=NN(C(=O)C1)c2ccccc2
SMILES	OpenEye OEToolkits	2.0.7	CC1=NN(C(=O)C1)c2ccccc2
Canonical SMILES	CACTVS	3.385	CC1=NN(C(=O)C1)c2ccccc2
Canonical SMILES	OpenEye OEToolkits	2.0.7	CC1=NN(C(=O)C1)c2ccccc2
InChI	InChI	1.03	InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
InChIKey	InChI	1.03	QELUYTUMUWHWMC-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank ID	DB12243
Name	Edaravone
Groups	approved investigational
Description	Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties.[A254257] It has three tautomers.[A19140] Edaravone works to scavenge reactive oxygen species, which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.[A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in 2001 for the treatment of acute ischemic stroke.[L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in October 2018.[L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made by the Committee for Medicinal Products for Human Use (CHMP) for a long-term study demonstrating the long-term efficacy and safety of edaravone.[L44002,L44012] Edaravone was also investigated in other disorders, such as Alzheimer's disease,[A19138] neuropathic pain, and ischemia-induced nerve injury.[A19139]
Synonyms	3-methyl-1-phenylpyrazol-5-one Phenyl methyl pyrazolone 1-phenyl-3-methyl-5-oxo-2-pyrazoline Edaravone 3-methyl-1-phenyl-2-pyrazolin-5-one Norphenazone 2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one Phenylmethylpyrazolone Methylphenylpyrazolone 3-methyl-1-phenyl-5-pyrazolone
Brand Names	Radicava Ors Radicava
Indication	Edaravone is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in the US and Canada.[L41810,L43952] It is also indicated to treat acute ischemic stroke in Japan.[A19140,A19141,L44007]
Categories	Antioxidants Central Nervous System Agents Compounds used in a research, industrial, or household setting Free Radical Scavengers Miscellaneous Central Nervous System Agents Nervous System Neuroprotective Agents OAT1/SLC22A6 Substrates OAT3/SLC22A8 Substrates Protective Agents Pyrazoles Pyrazolones UGT1A1 Substrates UGT1A6 substrate UGT1A9 Substrates UGT2B17 substrates UGT2B7 substrates
ATC-Code	N07XX14
CAS number	89-25-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
UDP-glucuronosyltransferase 1-1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate
UDP-glucuronosyltransferase 1-6	MACLLRSFQRISAGVFFLALWGMVVGDKLLVVPQDGSHWLSMKDIVEVLS...	unknown	substrate
UDP-glucuronosyltransferase 1-7	MARAGWTGLLPLYVCLLLTCGFAKAGKLLVVPMDGSHWFTMQSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 1-8	MARTGWTSPIPLCVSLLLTCGFAEAGKLLVVPMDGSHWFTMQSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 1-10	MARAGWTSPVPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMQSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
UDP-glucuronosyltransferase 2B17	MSLKWMSVFLLMQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRG...	unknown	substrate
Sulfotransferase	MSDDFLWFEGIAFPTMGFRSETLRKVRDEFVIRDEDVIILTYPKSGTNWL...	unknown	substrate
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
Solute carrier family 22 member 6	MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...	unknown	substrate
Solute carrier family 22 member 8	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682